Organization | Russian Academy of Medical Sciences

Russian Academy of Medical Sciences Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Moscow Russian Federation (1944)

Organization Overview

First Clinical Trial

2001

NCT04180774

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Boris Petrovsky's Scientific Center of Surgery Russian Academy of Medical Sciencies | Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS | Caencer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences | Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences | Central Clinical Hospital of the Russian Academy of Sciences | Federal Public State Institution Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of medical sciences | Federal State Budgetary Institution Russian Oncological Research Center named after N. N. Blokhin of the Russian Academy of Medical Sciences | Institute of Gene Biology of the Russian Academy of Sciences | Institute of Gene Biology Russian Academy of Sciences | Institute of internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences - Novosibirsk (Russia) | Mikhael Petrovich Kostinov | Mona Frolova | National Research Center for Hematology | National Research Center for Hematology, Russia | Nikolay Kamenshchikov | Prokhorov General Physics Institute of the Russian Academy of Sciences | Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS) | Research Institute of Influenza, Russian Academy of Medical Sciences | Research Institute of Nutrition of Russian Academy of Medical Sciences, Dpt Gastroenterology and Hepatology | Research Institute of Nutrition Russian Academy of Medical Sciences, Dpt Gastroenterology and Hepatology | Russian Academy of Medical Sciences | Russian Oncological Research Center n.a. N.N. Blokhin of the Russian Academy of Medical Sciences | Russian Oncological Research Center n.a. N. N. Blokhin RAMS | Russian Oncological Research Center n.a. N.N. Blokhin RAMS | Russian Oncological Scientific Center N.N.Blokhin Russian Academy of Sciences | Russian Scientific Center of Surgery | Russian Scientific Center of Surgery RAMS | Russian Society for Heart Failure | Russian Society of Clinical Oncology | Saint-Petersburg Clinical Hospital of the Russian Academy of Sciences | State Research Institute of Eye Disease of Russian Academy of Medical Sciences | Tomsk Mental Health Research Institute | Tomsk National Research Medical Center of the Russian Academy of Sciences | Tomsk NRMC | Vasily Isakov

Active Ingredients

Drugs in Phase 4 Trials (8)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

cytarabine (cytosar-u) (3 trials)

immunovac (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

polioxidonium (1 trial)

psyllium (1 trial)

resveratrol (1 trial)

torsemide (demadex) (1 trial)

Drugs in Phase 3 Trials (21)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

autologous hematopoietic cell (1 trial)

autologous mesenchymal stem cells (2 trials)

bendamustine (treanda) (1 trial)

cyclophosphamide (cytoxan) (5 trials)

dexamethasone (1 trial)

doxorubicin (Doxil) (5 trials)

doxycycline (vibramycin) (1 trial)

empegfilrastim (1 trial)

etoposide (vepesid) (2 trials)

ifosfamide (ifex) (2 trials)

methotrexate (2 trials)

naltrexone (revia) (2 trials)

polyprenols (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (4 trials)

sargramostim (leukine) (1 trial)

staphylokinase (1 trial)

testosterone (delatestryl) (1 trial)

vincristine (oncovin) (3 trials)

Drugs in Phase 2 Trials (36)

99mtc mip 1404 (1 trial)

adapt6 (2 trials)

alemtuzumab (campath) (1 trial)

allogeneic adipose derived mesenchymal stem cell (1 trial)

autologous dc-vaccines (1 trial)

bioactive factors, produced by m2 macrophage (2 trials)

bosutinib (bosulif) (1 trial)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (3 trials)

cblb612 (1 trial)

cd4+cd25+cd127lowfoxp3+ t regulatory cells (1 trial)

cefepime (maxipeme) (1 trial)

cisplatin (platinol) (4 trials)

cyclosporine (sandimmune) (2 trials)

dasatinib (sprycel) (1 trial)

docetaxel (taxotere) (1 trial)

eculizumab (Soliris) (1 trial)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (1 trial)

ftortiazinon (1 trial)

hyaluronic acid (1 trial)

imatinib (gleevec) (1 trial)

lenalidomide (revlimid) (1 trial)

mycophenolate (myfortic) (1 trial)

neovasculgen (1 trial)

nilotinib (tasigna) (1 trial)

nitric oxide (inomax) (3 trials)

paclitaxel (taxol) (6 trials)

procarbazine (matulane) (1 trial)

quisinostat (2 trials)

rostafuroxin (1 trial)

selumetinib (1 trial)

sirolimus (rapamune) (1 trial)

tacrolimus (prograf) (2 trials)

tag-7 gene modified inactivated tumor cells (1 trial)

tivozanib (Fotivda) (1 trial)

Drugs in Phase 1 Trials (5)

gemcitabine (gemzar) (1 trial)

ghb04l1 (1 trial)

indomethacin (indocin) (1 trial)

methylene blue (proveblue) (1 trial)

tolerogenic dendritic cells (1 trial)

Drugs in Other Trials (7)

99mtc-darping3 (1 trial)

asparaginase (elspar) (1 trial)

epinephrine (levophed) (1 trial)

formoterol (foradil) (1 trial)

ranibizumab (lucentis) (1 trial)

tiotropium (spiriva) (1 trial)

verapamil (calan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 3)

Acute Kidney Injury (Phase 2)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Autism Spectrum Disorder (Phase 2)

Autoimmune Diseases (Phase 1)

Brain Diseases (Phase 2)

Brain Ischemia (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiomyopathies (Phase 2)

Cardiovascular Diseases (Phase 3)

Chronic Traumatic Encephalopathy (Phase 2)

Cognition Disorders (Phase 2)

Collagen Diseases (Phase 1)

Communicable Diseases (Phase 2)

Connective Tissue Diseases (Phase 1)

Coronary Artery Disease (Phase 2)

Coronavirus Infections (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Developmental Disabilities (Phase 2)

Disease (Phase 2)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Esophagitis, Peptic (Phase 4)

Essential Hypertension (Phase 2)

Gastroesophageal Reflux (Phase 4)

Graft vs Host Disease (Phase 2)

Heart Failure (Phase 4)

Heart Valve Diseases (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypertension (Phase 4)

Hypogonadism (Phase 3)

Hypoxia (Phase 2)

Immune System Diseases (Phase 1)

Infarction (Phase 3)

Infections (Phase 2)

Influenza, Human (Phase 1)

Influenza in Birds (Phase 1)

Joint Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Kidney Neoplasms (Phase 2)

Language Development Disorders (Phase 2)

Leukemia (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Liver Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 4)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Mental Disorders (Phase 2)

Metabolic Syndrome (Phase 3)

Multiple Myeloma (Phase 3)

Musculoskeletal Diseases (Phase 1)

Myocardial Infarction (Phase 3)

Myocardial Reperfusion Injury (Phase 2)

Neoplasm Metastasis (Phase 2)

Neurocognitive Disorders (Phase 2)

Neutropenia (Phase 3)

Opioid-Related Disorders (Phase 3)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Ovarian Neoplasms (Phase 2)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Prostatic Neoplasms (Phase 2)

Pseudomonas Infections (Phase 2)

Psychotic Disorders (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Raynaud Disease (Phase 2)

Recurrence (Phase 2)

Renal Insufficiency (Phase 2)

Reperfusion Injury (Phase 2)

Rheumatic Diseases (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Speech Disorders (Phase 2)

Syndrome (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Tract Infections (Phase 2)

Vascular Diseases (Phase 3)

Virus Diseases (Phase 2)

Wounds and Injuries (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 54
# of Trial APIs: 77